Please assess the completion status of the following clinical trial:

Trial Title: Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 18 years of age or older~* Subjects must diagnosed with Community acquired pneumonia (CAP) or hospital acquired pneumonia (HAP) within 48 hours of diagnosis or presentation to hospital.~* Pneumonia will be defined as patients with a new radiographic finding(s) consistent with pneumonia and at least two of the following signs.~  1. Cough~ 2. Fever: axillary temperature \>37.5ºC or tympanic temperature \>38.5ºC~ 3. Hypothermia: axillary temperature \<34ºC or tympanic temperature \<35ºC.~ 4. Purulent sputum production or respiratory secretion.~ 5. Total peripheral white blood cell (WBC) count \>10,000/mm3; or \>15% band forms, regardless of total peripheral white count; or leucopenia with total WBC \< 4500/mm~ 6. Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony)~ 7. Hypoxemia - defined as partial O2 pressure \<60mmHg while the patient was breathing normal air or a decrease in the partial O2 pressure of \>= 25% from an initial range.~Exclusion Criteria:~1. Contraindication to ticagrelor (hypersensitivity or reaction to ticagrelor or another P2Y12 antagonist)~2. Active bleeding or major bleeding history (e.g. intracranial bleeding)~3. Clinically important anemia or thrombocytopenia (platelet count \<30)~4. Surgery within 30 days or anticipated major surgery (Thoracic, Abdominal, Brain; placement of lines, tracheostomy, and chest tubes are not considered major).~5. Oral anticoagulant therapy that cannot be stopped.~6. Inability or unwillingness of treating physician to reduce dose of aspirin to 81mg.~7. Fibrinolytic therapy in the last 24 hours.~8. Increased risk of bradycardic events - 2nd or 3rd degree heart block, bradycardia induced syncope - unless pacemaker in place.~9. Underlying immunodeficiency (HIV, neutropenia, receiving immunomodulating agents, active hematologic malignancy, functional or anatomical asplenia and hypogammaglobulinemia).~10. Moderate or severe liver disease defined by Child Pugh score \>7 using data from outpatient setting or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 fold upper limits of normal.~11. Renal dialysis~12. Concomitant therapy with strong CYP3A inhibitors; ketoconazole, itraconazole, voriconazole, saquinavir, nelfinavir, indinavir, or atazanavir.~13. Concomitant therapy with CYP3A substate with narrow therapeutic window: cyclosporin, quinidine.~14. Concomitant therapy with CYP3A inducer; rifampin/rifampicin, phenytoin, carbamazepine.~15. Pregnancy or lactation~16. Active treatment for cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ticagrelor (Type: EXPERIMENTAL): 180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
- placebo (Type: PLACEBO_COMPARATOR): One loading dose and then daily for 7 days or until hospital discharge if sooner

Based on this trial design, predict the completion outcome and termination type (if applicable).